In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish safe dosing regimen. Supplemental participants might be enrolled in the recognized monotherapy dosign routine. In Section B, contributors will acquire oral ruxolitinib and ABBV-744 will be provided as "increase-on" therapy. In Segment C, participants https://walesn001nyi4.blogunteer.com/profile